Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis Assessed by Transnasal Endoscopy (TNE)
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This study will enroll participants who have been diagnosed with Eosinophilic Esophagitis
(EoE). Upon study enrollment, the participant will begin a proton pump inhibitor (PPI),
Omeprazole 20mg twice daily. After taking Omeprazole for four weeks, the participant will
have a Transnasal Endoscopy, and biopsies will be taken to determine the histological change.
If the biopsies are abnormal, the participant continues Omeprazole and will undergo another
endoscopy at eight weeks. The study aims to determine the percentage of children with
Eosinophilic Esophagitis who improve with PPI use and to determine the length of time and
effectiveness of PPI therapy in the management of EoE. The investigators hypothesize that
following the initiation of PPI for treatment of Eosinophilic Esophagitis, biopsies obtained
will show decreasing eosinophil counts at four weeks, which is sooner than the previously
reported eight week period.